Please login to the form below

Not currently logged in

UK government raises concerns about Illumina’s $1.2bn takeover of PacBio

CMA concludes the merger will result in loss of market competition


The Competition and Markets Authority (CMA) has raised concerns that the merger of Illumina and Pacific Biosciences of California (PacBio) will lead to a loss of innovation in the DNA sequencing market.

The San Diego-based biotech is one of the leading companies working in genetics, and is a global supplier of next-generation DNA sequencing systems to a number of leading organisations around the world.

One of these includes Genomics England, with Illumina providing the genome sequencing systems for the 100,000 Genome Project. The Genomics EnglandDNA-sequencing systems it provides are crucial for projects such as this, which aim to research genetic diseases and aid faster drug development.

According to the CMA, Illumina holds around 80% of the global market share in this area, and 90% in the UK. It has provisionally concluded that the merger between Illumina and PacBio will cause a loss of competition between the two companies, and lead to fewer alternative options of DNA sequencing systems.

Illumina announced its plans to acquire PacBio in NoIlluminavember last year, for $1.2bn in an all-cash transaction.

The CMA is concerned that because DNA sequencing is a highly concentrated industry, that the deal between the two could lead to a reduction in the overall levels of innovation in the market.

The investigation also found that PacBio is one of Illumina’s closest competitors, and that internal documents from the companies have previously referred to each other as competitive threats.

This is consistent with the views of customers and the remaining competitors in the market.

“DNA sequencing is a highly concentrated industry and given the strength of Illumina in this market, and the limited number of alternative providers, the removal of an innovative competitor like PacBio is likely to have a significant impact on competition,” said Stuart McIntosh, the inquiry chair.

“This could harm critically important innovation in the systems created to support DNA sequencing and lead to less choice, higher prices or lower quality as a result of the merger,” he added.

Following the CMA's provisional findings, it has invited comments on possible remedies by 7 November 2019. However, it has already suggested that there is no reasonable remedy to its concerns.

Illumina had originally planned to close the transaction in mid-2019, but this was stalled by the CMA's investigation, which began in April. It now looks increasingly unlikely that it will be able to close the deal anytime soon.

Article by
Lucy Parsons

25th October 2019

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....